Pharsight

Drugs that contain Daptomycin

1. Cubicin patents expiration

CUBICIN's oppositions filed in EPO
CUBICIN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE39071 CUBIST PHARMS LLC Anhydro-and isomer-a-21978c cyclic peptides
Jun, 2016

(8 years ago)

US6852689 CUBIST PHARMS LLC Methods for administration of antibiotics
Sep, 2019

(4 years ago)

US6468967 CUBIST PHARMS LLC Methods for administration of antibiotics
Sep, 2019

(4 years ago)

US8058238 CUBIST PHARMS LLC High purity lipopeptides
Nov, 2020

(3 years ago)

US8129342 CUBIST PHARMS LLC High purity lipopeptides
Nov, 2020

(3 years ago)

US8003673 CUBIST PHARMS LLC Daptomycin for the treatment of biofilm and catheter salvage
Sep, 2028

(4 years from now)

US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-211) Sep 01, 2020
New Patient Population(NPP) Mar 29, 2020

Market Authorisation Date: 12 September, 2003

Treatment: Method for treating bacterial infection; Method of treating bacterial infections; Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloods...

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of CUBICIN before it's drug patent expiration?
More Information on Dosage

CUBICIN family patents

Family Patents

2. Cubicin Rf patents expiration

CUBICIN RF's oppositions filed in EPO
CUBICIN RF IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-211) Sep 01, 2020
New Patient Population(NPP) Mar 29, 2020

Market Authorisation Date: 12 September, 2003

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of CUBICIN RF before it's drug patent expiration?
More Information on Dosage

CUBICIN RF family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Daptomycin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357535 HOSPIRA Daptomycin formulations and uses thereof
Sep, 2033

(9 years from now)

US9655946 HOSPIRA Daptomycin formulations and uses thereof
Sep, 2033

(9 years from now)

Market Authorisation Date: 21 June, 2021

Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administerin...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

DAPTOMYCIN family patents

Family Patents

4. Daptomycin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11759497 XELLIA PHARMS APS Daptomycin formulations
Aug, 2038

(14 years from now)

Market Authorisation Date: 30 January, 2023

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

DAPTOMYCIN family patents

Family Patents

5. Dapzura Rt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173189 BAXTER HLTHCARE CORP Daptomycin formulations containing a combination of sorbitol and mannitol
Mar, 2041

(16 years from now)

Market Authorisation Date: 25 January, 2022

Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

DAPZURA RT family patents

Family Patents